Empery Asset Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-70,733
Closed -$504K 82
2022
Q1
$504K Sell
70,733
-129,267
-65% -$872K 2.37% 13
2021
Q4
$1.95M Buy
+200,000
New +$1.78M 4.07% 10

Other funds holding STLN

Empery Asset Management's STLN Position: Q2 2022 in Review

Empery Asset Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2022, closing a stake of 70,733 shares — an estimated $504K sold.

Empery Asset Management first reported a position in STLN in Q4 2021 and held it in 2 quarters. The position peaked at $1.95M in Q4 2021. 36 funds tracked by Wall St. Rank hold STLN as of Q2 2022.

  • Empery Asset Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Empery Asset Management sold 70,733 Starling Oncology Institute, Inc. Common Stock shares in Q2 2022, an estimated $504K.
  • Empery Asset Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Empery Asset Management's Starling Oncology Institute, Inc. Common Stock position peaked at $1.95M in Q4 2021.
  • 36 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2022.

Based on Empery Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.